Skip to main content
Premium Trial:

Request an Annual Quote

Roche Molecular Dx Revenue Slides 3 Percent as Applied Science Surges 10 Percent Over Past Nine Months

NEW YORK (GenomeWeb News) — Roche reported today that total receipts for its molecular diagnostics segment declined 3 percent in the first three quarters of 2007, compared with the same period one year ago, but overall revenue for the entire Diagnostics business rose 5 percent year over year.
 
Diagnostics sales overall rose to CHF 6.8 billion ($5.7 billion) while Molecular Diagnostics declined to CHF 856 million. However, excluding industrial reagents, sales in Molecular Diagnostics were up 3 percent.
 
Virology, “one of the business area’s largest segments,” rose 3 percent, driven by placements of the automated Cobas AmpliPrep/Cobas TaqMan platform in European, Asia-Pacific, and US markets, Roche said
 
Meantime, Roche Applied Science posted a 10-percent increase in nine-month sales. The segment's main growth drivers were the LightCycler 480 and Genome Sequencer 20 systems and research reagents, according to the company.
 
The company said all regions contributed to diagnostics sales in the first nine months, but pointed out particularly strong growth of 18 percent in the Asia-Pacific regions.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.